Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

100 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Editorial: The NAFLD-MAFLD conundrum.
Dalbeni A, Kumar R, Albhaisi S. Dalbeni A, et al. Front Endocrinol (Lausanne). 2023 Sep 12;14:1267341. doi: 10.3389/fendo.2023.1267341. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37772079 Free PMC article. No abstract available.
The impact of COVID-19 pandemic on well-being of Italian physicians: a report from the Italian Society of Internal Medicine (SIMI) national survey.
Romiti GF, Bencivenga L, Villani R, Cicco S, Cimellaro A, Dalbeni A, Talerico G, Pietrangelo A, Sesti G, Zaccone V; Giovani Internisti SIMI (GIS). Romiti GF, et al. Among authors: dalbeni a. Intern Emerg Med. 2023 Jan;18(1):53-65. doi: 10.1007/s11739-022-03108-4. Epub 2022 Oct 1. Intern Emerg Med. 2023. PMID: 36183031 Free PMC article.
Antihypertensive treatment changes and related clinical outcomes in older hospitalized patients.
Cicco S, D Abbondanza M, Proietti M, Zaccone V, Pes C, Caradio F, Mattioli M, Piano S, Marra AM, Nobili A, Mannucci PM, Pietrangelo A, Sesti G, Buzzetti E, Salzano A, Cimellaro A; Giovani Internisti Società Italiana di Medicina Interna (GIS-SIMI) and of the REPOSI Investigators. Cicco S, et al. Eur J Clin Invest. 2023 Apr;53(4):e13931. doi: 10.1111/eci.13931. Epub 2022 Dec 21. Eur J Clin Invest. 2023. PMID: 36453932 Free article.
Suboptimal outcomes of sorafenib as a second-line treatment after atezolizumab-bevacizumab for unresectable hepatocellular carcinoma.
Tovoli F, Pallotta DP, Vivaldi C, Campani C, Federico P, Palloni A, Dalbeni A, Soldà C, Lani L, Svegliati-Baroni G, Garajova I, Ielasi L, De Lorenzo S, Granito A, Stefanini B, Masi G, Marra F, Lonardi S, Brandi G, Daniele B, Auriemma A, Schiadà L, Chen R, Piscaglia F; ARTE study group. Tovoli F, et al. Among authors: dalbeni a. Dig Liver Dis. 2024 Aug 20:S1590-8658(24)00919-8. doi: 10.1016/j.dld.2024.07.035. Online ahead of print. Dig Liver Dis. 2024. PMID: 39168753 Free article.
Hepatic decompensation is the major driver of mortality in patients with HCC treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment.
Celsa C, Cabibbo G, Fulgenzi CAM, Battaglia S, Enea M, Scheiner B, D'Alessio A, Manfredi GF, Stefanini B, Nishida N, Galle PR, Schulze K, Wege H, Ciccia R, Hsu WF, Vivaldi C, Wietharn B, Lin RP, Pirozzi A, Pressiani T, Dalbeni A, Natola LA, Auriemma A, Rigamonti C, Burlone M, Parisi A, Huang YH, Lee PC, Ang C, Marron TU, Pinter M, Cheon J, Phen S, Singal AG, Gampa A, Pillai A, Roehlen N, Thimme R, Vogel A, Soror N, Ulahannan S, Sharma R, Sacerdoti D, Pirisi M, Rimassa L, Lin CY, Saeed A, Masi G, Schönlein M, von Felden J, Kudo M, Cortellini A, Chon HJ, Cammà C, Pinato DJ. Celsa C, et al. Among authors: dalbeni a. Hepatology. 2024 Jul 19. doi: 10.1097/HEP.0000000000001026. Online ahead of print. Hepatology. 2024. PMID: 39028886
Evaluation of ChatGPT as a Counselling Tool for Italian-Speaking MASLD Patients: Assessment of Accuracy, Completeness and Comprehensibility.
Pugliese N, Polverini D, Lombardi R, Pennisi G, Ravaioli F, Armandi A, Buzzetti E, Dalbeni A, Liguori A, Mantovani A, Villani R, Gardini I, Hassan C, Valenti L, Miele L, Petta S, Sebastiani G, Aghemo A, Nafld Expert Chatbot Working Group. Pugliese N, et al. Among authors: dalbeni a. J Pers Med. 2024 May 26;14(6):568. doi: 10.3390/jpm14060568. J Pers Med. 2024. PMID: 38929789 Free PMC article.
A global survey on the use of the international classification of diseases codes for metabolic dysfunction-associated fatty liver disease.
Zhang H, Targher G, Byrne CD, Kim SU, Wong VW, Valenti L, Glickman M, Ponce J, Mantzoros CS, Crespo J, Gronbaek H, Yang W, Eslam M, Wong RJ, Machado MV, Yu ML, Ghanem OM, Okanoue T, Liu JF, Lee YH, Xu XY, Pan Q, Sui M, Lonardo A, Yilmaz Y, Zhu LY, Moreno C, Miele L, Lupsor-Platon M, Zhao L, LaMasters TL, Gish RG, Zhang H, Nedelcu M, Chan WK, Xia MF, Bril F, Shi JP, Datz C, Romeo S, Sun J, Liu D, Sookoian S, Mao YM, Méndez-Sánchez N, Wang XY, Pyrsopoulos NT, Fan JG, Fouad Y, Sun DQ, Giannini C, Chai J, Xia ZF, Jun DW, Li GJ, Treeprasertsuk S, Li YX, Cheung TT, Zhang F, Goh GB, Furuhashi M, Seto WK, Huang H, Di Sessa A, Li QH, Cholongitas E, Zhang L, Silveira TR, Sebastiani G, Adams LA, Chen W, Qi X, Rankovic I, De Ledinghen V, Lv WJ, Hamaguchi M, Kassir R, Müller-Wieland D, Romero-Gomez M, Xu Y, Xu YC, Chen SY, Kermansaravi M, Kuchay MS, Lefere S, Parmar C, Lip GYH, Liu CJ, Åberg F, Lau G, George J, Sarin SK, Zhou JY, Zheng MH; MAFLD ICD-11 coding collaborators. Zhang H, et al. Hepatol Int. 2024 Aug;18(4):1178-1201. doi: 10.1007/s12072-024-10702-5. Epub 2024 Jun 15. Hepatol Int. 2024. PMID: 38878111
100 results